A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-015 in Patients With Advanced Malignant Tumors.
Overview
- Phase
- Phase 1
- Intervention
- LBL-015 for Injections
- Conditions
- Advanced Malignant Tumor
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
- Enrollment
- 25
- Locations
- 6
- Primary Endpoint
- Maximum tolerated dose (MTD)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
A Multicenter, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-015 in Patients With Advanced Malignant Tumors.
Detailed Description
This study is a single-arm, open-label, multi-center, dose-escalation and expansion phase I/II study to evaluate the safety, tolerability, pharmacokinetic characteristics, receptor occupancy, immunogenicity and efficacy of LBL-015 in patients with advanced malignant tumors.About 202 patients with advanced malignant tumor will be enrolled. The study is divided into Phase I study stage (dose escalation/PK expansion stage) and Phase II study stage (indication expansion stage). Patients with advanced or metastatic advanced malignant tumor who have failed previous standard treatment, are not suitable for standard treatment or have no standard treatment are included in the phase I study. After obtaining the RP2D in Phase I study ,Phase II study stage (indication expansion stage) was initiated.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form；
- •Age ≥18 and ≤75 years old at the time of signing the informed consent form, regardless of gender;
- •Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status Scale；
- •Have a life expectancy of at least 12 weeks；
- •There is adequate organ and bone marrow function,Conforms to laboratory test results;
- •Fertile men and women of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine devices, hormonal contraception, and correct use of condoms) from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug.
Exclusion Criteria
- •Received other unapproved investigational drug or treatment within 4 weeks prior to first dose of investigational drug；
- •Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug, or require elective surgery during the trial period；
- •Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin, and interferon；
- •Subjects with an active infection that currently requires intravenous anti infective therapy；
- •History of immunodeficiency, including positive HIV antibody test results；
- •Pregnant or lactating women；
- •The investigator's assessment that there may be other factors affecting compliance among participants or that some may not be suitable for inclusion in this study.
Arms & Interventions
LBL-015
Drug: LBL-015 for Injection，Initial dose - MTD; Q2W
Intervention: LBL-015 for Injections
Outcomes
Primary Outcomes
Maximum tolerated dose (MTD)
Time Frame: 28 days after the first dose.
MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycles. It was used to evaluate the tolerability.
Dose-limiting toxicities（DLT）
Time Frame: 28 days after the first dose
DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. It was used to evaluate the safety.
Secondary Outcomes
- Cmax(From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
- Tmax(From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
- immunogenicity(From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)
- Pharmacodynamic (PD) index(From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy)